NNI-351

From Wikipedia, the free encyclopedia
NNI-351
NNI-351.svg
Clinical data
Routes of
administration
By mouth
Identifiers
  • 4-(3-Cyano-6-ethoxyquinolin-2-yl)-N-(2-fluorophenyl)-1,4-diazepane-1-carbothioamide
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC24H24FN5OS
Molar mass449.55 g·mol−1
3D model (JSmol)
  • CCOC1=CC2=C(C=C1)N=C(C(=C2)C#N)N3CCCN(CC3)C(=S)NC4=CC=CC=C4F
  • InChI=1S/C24H24FN5OS/c1-2-31-19-8-9-21-17(15-19)14-18(16-26)23(27-21)29-10-5-11-30(13-12-29)24(32)28-22-7-4-3-6-20(22)25/h3-4,6-9,14-15H,2,5,10-13H2,1H3,(H,28,32)
  • Key:RQXUPDSAFGWKMO-UHFFFAOYSA-N

NNI-351 is an orally active inhibitor of DYRK1A and neurogenesis enhancer which is under development by NeuroNascent, Inc. for the treatment of Down syndrome, depression, and post-traumatic stress disorder (PTSD).[1][2] As of 2017, it is in the preclinical development stage, and has yet to progress to human clinical trials.[1] In July of 2022, NNI-351 was granted Orphan Drug status by the FDA for the treatment of Fragile X syndrome.[3]

See also[edit]

References[edit]

  1. ^ a b "Research programme: Psychiatric and neurological disorders therapeutics - Neuronascent - AdisInsight".
  2. ^ Froestl W, Muhs A, Pfeifer A (2013). "Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes". J. Alzheimer's Dis. 33 (3): 547–658. doi:10.3233/JAD-2012-121537. PMID 23042218.
  3. ^ "Neuronascent Receives FDA Orphan Drug Designation for NNI-351 Treatment of Fragile X Syndrome". GlobeNewswire News Room. GlobalNewsWire. 1 June 2022. Retrieved 15 January 2023.

External links[edit]